source
- Merck and Moderna’s melanoma vaccine shows positive Phase 3 results, boosting investor confidenceMerck and Moderna announced that their personalized melanoma vaccine met the primary endpoint of recurrence‑free survival in a Phase 3 trial when given together with Keytruda. The study showed pati…
- Merck and Moderna report positive late-stage melanoma vaccine results, adding to 2026 cancer breakthrough yearMerck and Moderna announced that their personalized mRNA neoantigen vaccine achieved positive outcomes in a late-stage trial for melanoma patients. The data suggest the vaccine can stimulate an imm…STAT · 2mo agoPositive readoutPositive